meropenem fresenius 500 mg
neopharm (israel) 1996 ltd - meropenem as anhydrous - powder for solution for inj/inf - meropenem as anhydrous 500 mg/vial - meropenem - for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
meropenem 500 mg powder for solution for injection/infusion
as kalceks - meropenem trihydrate - powder for solution for injection/infusion - meropenem
meropenem 500 mg powder for solution for injection/infusion
steriscience b.v. - meropenem trihydrate - powder for solution for injection/infusion - meropenem
meropenem 500 mg powder for solution for injection or infusion
rowex ltd - meropenem trihydrate - powder for solution for injection/infusion - meropenem
meropenem anfarm 1 g
k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency
meropenem anfarm 500 mg
k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 500 mg/vial - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency
meropenem sandoz
novartis new zealand ltd - meropenem trihydrate 1.14155 g equivalent to of meroopenem 1 g; - powder for injection - 1 g - active: meropenem trihydrate 1.14155 g equivalent to of meroopenem 1 g excipient: nitrogen sodium carbonate - indicated for treatment, in adults and children, of lower respiratory tract infections.
meropenem 0.5 g powder for solution for injection or infusion
accord healthcare ireland ltd. - meropenem - powder for solution for injection/infusion - 0.5 gram(s) - carbapenems; meropenem
mepran 500 iv injection powder for solution for injection/infusion
kopran limited c/o. surgilinks ltd kopran limited 1076,parijat house, dr. e.moses - meropenem for injection usp - powder for solution for injection/infusion - meropenem 500 mg (as meropenem trihydrate) - meropenem
meropenem hospira
hospira uk limited - meropenem trihydrate - pdr for soln inj/inf - 500 milligram - meropenem